

Response to Article “Autophagy Inhibits Inflammation via Down-Regulation of p38 MAPK/mTOR Signaling Cascade in Endothelial Cells” [Letter]

Masri Sembiring Maha, Novaria Sari Dewi Panjaitan 

Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Cibinong, West Java, Indonesia

Correspondence: Novaria Sari Dewi Panjaitan, Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Jl. Raya Bogor No. 490, Cibinong – Bogor Km. 46, Cibinong, West Java, Indonesia, Email nova014@brin.go.id

Dear editor

The work performed by Zhou et al regarding the regulative mechanism of autophagy that inhibits inflammation via down-regulation of p38 MAPK/mTOR signaling cascade in endothelial cells has been reviewed and much appreciated.¹ In their study, rapamycin-induced autophagy was shown and proven to be able to improve the function of endothelial cells in psoriasis, the chronic immune-mediated skin disease. Their results suggested that approaches to induce autophagy could be used to ameliorate psoriasis. This work supplied novelty and promising ideas in the autophagy and psoriasis fields. However, a few suggestions and recommendations for improving the further study in the fields are provided.

Autophagy is a key process by which cells degrade their components to maintain homeostasis. There are some previous studies reporting the role of autophagy and its regulation in skin diseases, including skin pigmentation and skin inflammation. Previously reported data suggested that modulation of autophagy or activation of aryl hydrocarbon receptors (AHRs) could affect processes involved in epidermal differentiation and contribute to the pathogenesis of chronic inflammatory skin diseases with skin barrier abnormalities such as psoriasis. This previous study had unraveled the role of autophagy contribution in improving psoriasis by treating the polycytokine-stimulated human keratinocytes and psoriasis skin biopsies tested in their *in vitro* and *in vivo* studies.²

In their study, Zhou et al reported that the induction of autophagy by rapamycin could improve the function of M5 cytokines-induced inflamed endothelial cells proven by a significant declined NO content and NOS activity in HUVECs compared with that in controls.¹ However, a negative control, a control treated with autophagy inhibitor, such as PI3K/mTOR inhibitor, was not shown or performed in this study. A comprehensive study which included both a positive and negative control could be used as more fundamental information regarding a novelty in a particular objective.³ Therefore, an appropriate negative control is much recommended to be included in further study.

There are also other approaches to induce autophagy in *in vitro* and *in vivo* studies. The induction of autophagy by an autophagy inducer, Synthesized Aquatide™, has been recently reported to play an important role in maintaining overall health and skin health in animal model dogs with underlying diseases.⁴ Therefore, an *in vivo* study is recommended to be performed as part of the further study.

Regardless, we appreciated the outcomes reported on the mechanism involved in this study, that autophagy could inhibit M5 cytokines-induced inflammation through the p38-MAPK/mTOR pathway in HUVEC cells. Their data confirmed and added more information on a previously reported study which stated that the inhibition of autophagy was associated with PI3K/AKT/mTOR and eNOS signaling pathways in HUVEC cells.⁵

Acknowledgments

All authors would like to acknowledge Dr. Sunarno and all researchers in Center for Biomedical Research BRIN for the continuous support.

Author Contributions

Both authors have equal contribution in conceiving the critical design and thoughts written and discussed in the letter manuscript, writing and revising the manuscript. Both authors agreed the final form of the manuscript.

Disclosure

All authors stated that there is no conflict of interest regarding this communication.

References

1. Zhou L, Wang J, Hou H, et al. Autophagy inhibits inflammation via down-regulation of p38 MAPK / mTOR signaling cascade in endothelial cells. *Clin Cosmet Investig Dermatol*. 2023;16:659–669. doi:10.2147/CCID.S405068
2. Kim HR, Kim HO, Kim JC, Park CW, Chung BY. Effects of autophagy modulators and dioxin on the expression of epidermal differentiation proteins on psoriasis-like keratinocytes in vitro and ex vivo. *Clin Cosmet Investig Dermatol*. 2022;15:1149–1156. doi:10.2147/CCID.S368105
3. Liu T, Zhang J, Li K, Deng L, Wang H. Combination of an autophagy inducer and an autophagy inhibitor: a smarter strategy emerging in cancer therapy. *Front Pharmacol*. 2020;11:1–14. doi:10.3389/fphar.2020.00408
4. Kim Y, Lee SH, Song Y, Jeong S, Kim HJ. Induction of autophagy improves skin and hair conditions in dogs with underlying diseases. *Front Vet Sci*. 2023;10(10). doi:10.3389/fvets.2023.1078259
5. Zhang G, He C, Wu Q, et al. Impaired autophagy induced by oxLDL/ β 2GPI/anti- β 2GPI complex through PI3K/AKT/mTOR and eNOS signaling pathways contributes to endothelial cell dysfunction. *Oxid Med Cell Longev*. 2021;2021. doi:10.1155/2021/6662225

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical, Cosmetic and Investigational Dermatology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical, Cosmetic and Investigational Dermatology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical, Cosmetic and Investigational Dermatology

Dovepress

Publish your work in this journal

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal>

<https://doi.org/10.2147/CCID.S412865>